Adelaide University researchers have found a DNA “switch” that helps the body stop the growth of the most common form of breast cancer, providing new insights that could help with future treatments
A KAIST-led research team has found that a protein involved in gene regulation can suppress the harmful aggregation of amyloid-beta, a peptide associated with Alzheimer’s disease. The approach also reduced the toxicity of protein aggregates that had already formed.
A small subset of vulnerable DNA sites can make cancer cells highly sensitive to targeted drugs called PARP inhibitors, a new study shows.
A patient has undergone pioneering stem-cell therapy to treat Parkinson’s disease, the Japanese drugmaker behind the treatment said on Friday, in a world first following its conditional approval in the country.
An overlooked mechanism in lung cancer tumors may help explain why most patients don’t respond to immunotherapy, according to new research led by Olga Anczuków, professor at The Jackson Laboratory for Genomic Medicine in Farmington, Connecticut, and deputy director of the NCI-designated Jackson Laboratory Cancer Center.
Tufts-led team pursues promising new approach to preventing and fighting the bacterium that causes the tick-borne illness
Huntington’s disease is caused by repetitive “stutters” in DNA—specifically repeated CAG sequences—that expand abnormally over time, leading to toxic protein accumulation that contributes to the progression of the disease. There is currently no cure for this rare and fatal genetic disease.
A needle-free vaccination method protected mice against the viruses that cause COVID-19 and flu, offering a possible new way to deliver mRNA vaccines while limiting unwanted inflammation.
An AI model created by researchers at King’s can detect signs of faulty repair mechanisms in ovarian cancer cells, potentially leading to a low-cost, widely accessible diagnostic tool in the future.
Despite advances in early-stage lung cancer treatment, a significant number of patients experience disease recurrence after surgery or initial therapy. A study has now demonstrated that a blood test (liquid biopsy) can reliably detect lingering lung cancer traces even in the earliest clinical stages, long before a tumor is large enough to show up on a scan.